Business Description
Climb Bio Inc
NAICS : 325412
SIC : 2834
ISIN : US28658R1068
Total Employee Number:
29Description
Climb Bio Inc is a clinical-stage biotechnology company focused on developing therapeutics for patients with immune-mediated diseases. Its pipeline includes Budoprutug, an anti-CD19 monoclonal antibody being developed for B-cell mediated diseases such as primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus, and CLYM116, an anti-APRIL monoclonal antibody being developed for the treatment of IgA nephropathy.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 228.74 | |||||
Equity-to-Asset | 0.97 | |||||
Debt-to-EBITDA | -0.01 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 16.5 | |||||
3-Year EPS without NRI Growth Rate | 19.3 | |||||
3-Year FCF Growth Rate | 17.3 | |||||
3-Year Book Growth Rate | -11.5 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | -16.03 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 82.1 | |||||
9-Day RSI | 72.12 | |||||
14-Day RSI | 66.79 | |||||
3-1 Month Momentum % | 60.2 | |||||
6-1 Month Momentum % | 131.03 | |||||
12-1 Month Momentum % | 803.97 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 27.86 | |||||
Quick Ratio | 27.86 | |||||
Cash Ratio | 26.91 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -21.6 | |||||
Shareholder Yield % | -0.04 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -30.53 | |||||
ROA % | -29.47 | |||||
ROIC % | -75.27 | |||||
3-Year ROIIC % | -40.2 | |||||
ROC (Joel Greenblatt) % | -7936.06 | |||||
ROCE % | -34.67 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 4.25 | |||||
Price-to-Tangible-Book | 4.25 | |||||
EV-to-EBIT | -10.73 | |||||
EV-to-EBITDA | -10.75 | |||||
EV-to-Forward-Revenue | 46.6 | |||||
EV-to-FCF | -12.09 | |||||
| Price-to-Net-Current-Asset-Value | 5.77 | |||||
| Price-to-Net-Cash | 5.98 | |||||
Earnings Yield (Greenblatt) % | -9.32 | |||||
FCF Yield % | -7.07 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:CLYM
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Climb Bio Inc Executives
DetailsGF Value™
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -0.78 | ||
| Beta | -1.1534 | ||
| 3-Year Sharpe Ratio | 0.74 | ||
| 3-Year Sortino Ratio | 2.3 | ||
| Volatility % | 124.97 | ||
| 14-Day RSI | 66.79 | ||
| 14-Day ATR ($) | 0.911945 | ||
| 20-Day SMA ($) | 11.44775 | ||
| 12-1 Month Momentum % | 803.97 | ||
| 52-Week Range ($) | 1.18 - 13.46 | ||
| Shares Outstanding (Mil) | 57.26 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Climb Bio Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Climb Bio Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-06 | In 130 days | ||
| Second quarter earnings results for 2026 | 2026-08-12 | In 44 days | ||
| General meeting for 2026 | 2026-06-05 09:00 | 10.91 (+6.44%) | ||
| Jefferies Global Healthcare Conference | 2026-06-04 14:35 | 10.44 (-5.18%) | ||
| H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ | 2026-05-19 11:00 | 9.88 (-8.52%) | ||
| First quarter earnings results for 2026 | 2026-05-07 | 12.22 (+6.45%) | ||
| R&D Spotlight: Budoprutug and the CD19 Opportunity | 2026-05-05 08:00 | 9.69 (+9.12%) | ||
| Leerink Global Healthcare Conference | 2026-03-09 14:20 | 7.18 (-2.45%) | ||
| Annual report for 2025 | 2026-03-05 | 7.28 (+1.39%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-05 | 7.28 (+1.39%) |
Show
Entries
Climb Bio Inc Frequently Asked Questions
What is Climb Bio Inc(CLYM)'s stock price today?
The current price of CLYM is $13.16. The 52 week high of CLYM is $13.46 and 52 week low is $1.18.
When is next earnings date of Climb Bio Inc(CLYM)?
The next earnings date of Climb Bio Inc(CLYM) is 2026-08-12 Est..
Does Climb Bio Inc(CLYM) pay dividends? If so, how much?
Climb Bio Inc(CLYM) does not pay dividend.
Guru Commentaries on NAS:CLYM
No articles.
Press Release
Articles on Climb Bio Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers